Kiniksa Pharmaceuticals Corporation
http://www.kiniksa.com
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Kiniksa Pharmaceuticals Corporation
Kiniksa’s Mavrilimumab Fails In Late-Stage COVID-19 Trial, Doubles Back On Arcalyst
The firm’s anti GM-CSF candidate has underwhelmed in a study in hospitalized COVID-19 patients, triggering renewed focus on its recently launched product Arcalyst for recurrent pericarditis.
Keeping Track: US FDA Approves J&J’s Novel MS Drug Ponvory, Breakthrough Pericarditis Claim For Kiniksa’s Arcalyst
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Coronavirus Notebook: EMA Publishes Veklury Clinical Data, Head Of UK Vaccines Taskforce Comes Under Fire
Transparency is the order of the day as Médecins Sans Frontières calls for more disclosure on vaccine deals signed by Sanofi/GSK and other companies.
Finance Watch: With Four More IPOs, July May Match Or Exceed June’s 14
Public Company Edition: iTeos, Annexon, Nurix and Inozyme went public on 23 July and now CureVac has added its name to the IPO queue for what could be a large offering. Also, BioNTech raises $511.5m as COVID-19 vaccine progresses and PTC gets $650m from sale of risdiplam royalties.
Company Information
- Industry
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- Kiniksa Pharmaceuticals, Ltd.
- Kiniksa Pharmaceuticals Corp.
- Primatope Therapeutics, Inc.